ERBB2 and breast cancer: The ongoing OFSET trial (NCT05879926) will clarify whether endocrine therapy plus ovarian function suppression (OFS) will yield comparable results to chemotherapy followed by endocrine therapy plus OFS in pre-menopausal patients with pN1 HR+/HER2– early BC and an RS of 0–25.